| 1 |
32084420 | Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib. | 2020 May 5 |
2 |
| 2 |
30612311 | Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. | 2019 Oct |
1 |
| 3 |
28443467 | Effect of irinotecan on HMGB1, MMP9 expression, cell cycle, and cell growth in breast cancer (MCF-7) cells. | 2017 Apr |
1 |
| 4 |
26842236 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors. | 2016 Jul 1 |
1 |
| 5 |
25685067 | Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status. | 2015 |
1 |
| 6 |
26257651 | Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. | 2015 |
1 |
| 7 |
26438158 | PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway. | 2015 Dec |
1 |
| 8 |
24215868 | Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. | 2014 Feb 28 |
1 |
| 9 |
23054213 | The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. | 2013 Apr |
1 |
| 10 |
23653048 | Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. | 2013 Jul |
3 |
| 11 |
23913164 | TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells. | 2013 Oct |
2 |
| 12 |
21609311 | Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. | 2011 |
1 |
| 13 |
19208614 | The potential role and application of PARP inhibitors in cancer treatment. | 2009 |
1 |
| 14 |
19604089 | Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. | 2009 Jul |
1 |
| 15 |
18347181 | Irinotecan pharmacogenetics: influence of pharmacodynamic genes. | 2008 Mar 15 |
1 |
| 16 |
17431115 | S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells. | 2007 Apr |
1 |
| 17 |
16809434 | Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. | 2006 Aug |
7 |
| 18 |
12907654 | Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. | 2003 Aug 1 |
1 |
| 19 |
11593056 | Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. | 2001 Oct |
3 |
| 20 |
10100720 | Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. | 1999 Mar |
1 |